# US 2008/0187905 A1 · Nucleic acid isolation using polidocanol and derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187905 A1
- Document ID: US20080187905A1
- Status: Published application
- Kind: A1
- Application number: 12/001,670
- Filed: 2007-12-11
- Published: 2008-08-07
- Earliest claimed: 2006-12-11
- Assignees: Roche Molecular Systems, Inc.
- Inventors: Sigrid Adie; Hermann Leying; Nicole Nachbaur; Eberhard Russmann
- Web page: https://patentgrep.com/patent/US20080187905A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This invention relates to a composition comprising a chaotropic agent, a buffering substance, and 0.5 to 5% (V/V) polidocanol or a derivative thereof. The invention is further related to uses of this composition and to a kit comprising the composition according to the invention. The invention is further related to a method for the detection of a nucleic acid in a biological sample comprising the steps of incubating the biological sample in the presence of a chaotropic agent, a buffering substance, and 0.5 to 5% (V/V) polidocanol or a derivative thereof, optionally isolating the nucleic acid, optionally amplifying the nucleic acid, and detecting the nucleic acid. The invention is further related to a method for the purification of a nucleic acid in a biological sample comprising the steps of incubating the biological sample in the presence of a chaotropic agent, a buffering substance, and 0.5 to 5% (V/V) polidocanol or a derivative thereof and isolating the nucleic acid thereby purifying the nucleic acid.

## Claims

### Claim 1

A composition comprising
a chaotropic agent,
a buffering substance, and
0.5 to 5% (V/V) polidocanol or a derivative thereof.

### Claim 2 (depends on 1)

The composition according to claim 1 wherein the composition comprises 0.5 to 3% (V/V) polidocanol or a derivative thereof.

### Claim 3 (depends on 1)

The composition according to claim 1 wherein the composition comprises 1 to 4.5% (V/V) polidocanol or a derivative thereof.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the chaotropic agent is selected from the group consisting of guanidinium thiocyanate, guanidinium chloride and urea.

### Claim 5 (depends on 1)

The composition according to claim 1 wherein the buffering substance is selected from the group consisting Tris-(hydroxymethyl)-aminomethane (TRIS), phosphate, N-(2-hydroxyethyl)-piperazine-N′-(2-ethanesulfonic acid) (HEPES), acetate and citrate.

### Claim 6 (depends on 1)

The composition according to claim 1 wherein the pH of the composition is between 3 and 5.

### Claim 7 (depends on 1)

The composition according to claim 1 wherein the composition further comprises a reducing agent.

### Claim 8 (depends on 1)

The composition according to claim 1 wherein the composition comprises 4 M guanidinium thiocyanate, 50 mM Na-Citrate, 1% (V/V) DTT, 3% (V/V) polidocanol, pH4.

### Claim 9 (depends on 1)

The composition according to claim 1, further comprising a protease.

### Claim 10 (depends on 1)

A kit comprising a composition according to claim 1.

### Claim 11 (depends on 10)

The kit according to claim 10, further comprising a nucleic acid binding material.

### Claim 12 (depends on 11)

The kit according to claim 11, wherein the nucleic acid binding material comprises magnetic glass particles.

### Claim 13 (depends on 10)

The kit according to claim 10, further comprising a washing buffer and an elution buffer.

### Claim 14

A method for the detection of a nucleic acid in a biological sample, comprising:
a) incubating the biological sample in the presence of a chaotropic agent, a buffering substance, and 0.5 to 5% (V/V) polidocanol or a derivative thereof,
b) optionally isolating the nucleic acid,
c) optionally amplifying the nucleic acid, and
d) detecting the nucleic acid.

### Claim 15 (depends on 14)

The method according to claim 14, whereby in the amplifying step c) the nucleic acid is amplified by the polymerase chain reaction.

### Claim 16

A method for the purification of a nucleic acid in a biological sample, comprising:
a) incubating the biological sample in the presence of a chaotropic agent, a buffering substance, and 0.5 to 5% (V/V) polidocanol or a derivative thereof,
b) isolating the nucleic acid, thereby purifying the nucleic acid.

### Claim 17 (depends on 14)

The method according to claim 14, wherein in step a) the biological sample is incubated in the presence of a chaotropic agent, a buffering substance, and 0.5 to 3% (V/V) polidocanol or a derivative thereof.

### Claim 18 (depends on 14)

The method according to claim 14, whereby the isolating step b) comprises binding the nucleic acid to a nucleic acid binding material, optionally washing the nucleic acid bound to the material and eluting the nucleic acid from the material.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the nucleic acid binding material comprises magnetic glass particles.

### Claim 20 (depends on 14)

The method according to claim 14, wherein the biological sample is a fluid from the human or animal body, said fluid being selected from the group consisting of blood, blood plasma, blood serum and urine.

### Claim 21 (depends on 14)

The method according to claim 14, wherein the nucleic acid comprises DNA or RNA or both.

### Claim 22 (depends on 14)

The method according to claim 14, wherein the nucleic acid is derived from a microorganism or a virus.

### Claim 23 (depends on 14)

The method according to claim 14, wherein the nucleic acid is derived from a member of the group consisting of a hepatitis A virus, hepatitis B virus, the hepatitis C virus, the human immunodeficiency virus or the cytomegalovirus.
